bioRxiv (Cold Spring Harbor Laboratory)
March 24, 2026
Kenneth Shinozuka, Mattia Rosso, Anna Chaiken et al.
1 citation
Abstract Post-traumatic stress disorder (PTSD) is a debilitating condition that affects millions of veterans. A recent observational study in 30 veterans showed that a single dose of the atypical psychedelic ibogaine can be highly effective at treating PTSD up to twelve months later. Although a prior study demonstrated that ibogaine transiently alters electroencephalography (EEG) power in...
iScience
February 21, 2026
Andrew Geoly, John P. Coetzee, Derrick Matthew Buchanan et al.
= 22). Longitudinal analyses assessed cortical thickness, subcortical volume, and predicted brain age (pBA), estimated from T1 scans. pBA was significantly reduced at 1 month relative to baseline (-1.3 years). Cortical thickness analysis revealed post-treatment increases in 11 regions. Subcortical analyses revealed significant volumetric expansion in 8 regions. Magnesium-ibogaine therapy was...
Biological Psychiatry Cognitive Neuroscience and Neuroimaging
February 1, 2026
Malvika Sridhar, Azeezat Azeez, Andrew Geoly et al.
BackgroundIbogaine was recently found to result in significant functional improvements in treating the sequelae of traumatic brain injury (TBI) among Special Operations Forces veterans (SOVs). In the current study, we used multimodal neuroimaging to elucidate the neural correlates of ibogaine in 30 male SOVs who received ibogaine treatment.MethodsArterial spin labeling and blood oxygen...
Research Square
December 17, 2025
Camarin E. Rolle, Nolan Williams, Afik Faerman et al.
Abstract Traumatic brain injury (TBI) can result in chronic functional disability and is associated with persistent psychiatric symptoms, including posttraumatic stress disorder (PTSD), depression, and anxiety. Ibogaine, an oneirogenic alkaloid with unique pharmacological properties, has shown initial promise as a potential treatment for TBI-related sequelae. We previously observed large...
Journal of Affective Disorders
November 18, 2025
Randi Brown, Jennifer I. Lissemore, Kenneth Shinozuka et al.
1 citation
Ibogaine is an atypical psychedelic that evokes unique subjective effects, including mystical experiences. Mystical experiences have shown a mediating effect on clinical improvements following treatment with several psychedelic substances; however, the relationship between mystical experiences and clinical outcomes following ibogaine remains unclear. We examined the association between mystical...